Strategies for Derisking Translational Processes for Biomedical Technologies.

Inefficient translational processes for technology-oriented biomedical research have led to some prominent and frequent failures in the development of many leading drug candidates, several designated investigational drugs, and some medical devices, as well as documented patient harm and postmarket product withdrawals. Derisking this process, particularly in the early stages, should increase translational efficiency and streamline resource utilization, especially in an academic setting. In this opinion article, we identify a 12-step guideline for reducing risks typically associated with translating medical technologies as they move toward prototypes, preclinical proof of concept, and possible clinical testing. Integrating the described 12-step process should prove valuable for improving how early-stage academic biomedical concepts are cultivated, culled, and manicured toward intended clinical applications.

[1]  Chi-Ping Day,et al.  Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges , 2015, Cell.

[2]  Shein-Chung Chow,et al.  Adaptive clinical trial design. , 2014, Annual review of medicine.

[3]  Andrew L. Kung,et al.  A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response , 2012, Nature.

[4]  Richard Simon,et al.  Genomic biomarkers in predictive medicine. An interim analysis , 2011, EMBO molecular medicine.

[5]  Larry Rubinstein,et al.  Phase 0 Clinical Trials: Conceptions and Misconceptions , 2008, Cancer journal.

[6]  Georg N Duda,et al.  Qualifying stem cell sources: how to overcome potential pitfalls in regenerative medicine? , 2016, Journal of tissue engineering and regenerative medicine.

[7]  Christie M. Ballantyne,et al.  Lipid lowering with PCSK9 inhibitors , 2014, Nature Reviews Cardiology.

[8]  Janet Woodcock,et al.  Expediting drug development--the FDA's new "breakthrough therapy" designation. , 2013, The New England journal of medicine.

[9]  C. Mehta,et al.  The future of drug development: advancing clinical trial design , 2009, Nature Reviews Drug Discovery.

[10]  Jong-Myon Bae,et al.  Value-based medicine: concepts and application , 2015, Epidemiology and health.

[11]  M Liebsch,et al.  Lessons learned from validation of in vitro toxicity test: from failure to acceptance into regulatory practice. , 2001, Toxicology in vitro : an international journal published in association with BIBRA.

[12]  Ulrich Dirnagl,et al.  Distinguishing between Exploratory and Confirmatory Preclinical Research Will Improve Translation , 2014, PLoS biology.

[13]  Petra Reinke,et al.  Gene therapy: a possible future standard for HIV care. , 2015, Trends in biotechnology.

[14]  B. Ruggeri,et al.  Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. , 2014, Biochemical pharmacology.

[15]  Petra Reinke,et al.  Putting a price tag on novel autologous cellular therapies. , 2016, Cytotherapy.

[16]  U. Dirnagl,et al.  Biomedical research: increasing value, reducing waste , 2014, The Lancet.

[17]  Brian D. Wright,et al.  Patents versus patenting: implications of intellectual property protection for biological research , 2009, Nature Biotechnology.

[18]  Gopi Shankar,et al.  A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs , 2007, Nature Biotechnology.

[19]  V. Drozdoff,et al.  Licensing biotech intellectual property in university-industry partnerships. , 2015, Cold Spring Harbor perspectives in medicine.

[20]  Kwok-Kin Wong,et al.  New cast for a new era: preclinical cancer drug development revisited. , 2013, The Journal of clinical investigation.

[21]  Petra Reinke,et al.  The business case for cell and gene therapies , 2014, Nature Biotechnology.

[22]  Marcus J Schultz,et al.  Critical factors in the translation of improved antimicrobial strategies for medical implants and devices. , 2013, Biomaterials.

[23]  Mohamed Abou-El-Enein,et al.  Deciphering the EU clinical trials regulation , 2016, Nature Biotechnology.

[24]  Jacqueline Corrigan-Curay,et al.  Genome Editing Technologies: Defining a Path to Clinic: Genomic Editing: Establishing Preclinical Toxicology Standards, Bethesda, Maryland 10 June 2014. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  Marcus J Schultz,et al.  Biomaterial-Associated Infection: Locating the Finish Line in the Race for the Surface , 2012, Science Translational Medicine.

[26]  Brian A. Nosek,et al.  Power failure: why small sample size undermines the reliability of neuroscience , 2013, Nature Reviews Neuroscience.

[27]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[28]  R G Richards,et al.  Challenges in linking preclinical anti-microbial research strategies with clinical outcomes for device-associated infections. , 2014, European cells & materials.

[29]  David W Grainger,et al.  Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments. , 2014, Advanced drug delivery reviews.

[30]  Petra Reinke,et al.  A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV. , 2014, Trends in molecular medicine.

[31]  Emil D Kakkis,et al.  Accessing the accelerated approval pathway for rare disease therapeutics , 2016, Nature Biotechnology.

[32]  S. Alzghari,et al.  Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[33]  Lee Harland,et al.  Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery , 2009, Nature Reviews Drug Discovery.

[34]  Ivan Rusyn,et al.  In vitro models for liver toxicity testing. , 2013, Toxicology research.

[35]  Mark Kessel,et al.  The problems with today's pharmaceutical business—an outsider's view , 2011, Nature Biotechnology.

[36]  G. Vaidyanathan.  Redefining Clinical Trials: The Age of Personalized Medicine , 2012, Cell.

[37]  Stuart A. Lipton,et al.  Partnering with Big Pharma—What Academics Need to Know , 2016, Cell.

[38]  Sylvie Chabaud,et al.  Experimental designs for small randomised clinical trials: an algorithm for choice , 2013, Orphanet Journal of Rare Diseases.

[39]  Emily S. Sena,et al.  Bringing rigour to translational medicine , 2014, Nature Reviews Neurology.

[40]  Ali Khademhosseini,et al.  Organs-on-a-chip: a new tool for drug discovery , 2014, Expert opinion on drug discovery.

[41]  David W Grainger,et al.  Cell-based drug testing; this world is not flat. , 2014, Advanced drug delivery reviews.